Literature DB >> 2231947

Transrectal ultrasonography in the evaluation of the infertile man: a report of 3 cases.

L Patterson1, J P Jarow.   

Abstract

The traditional evaluation of the infertile man with azoospermia or low ejaculate volume includes determination of serum testosterone and follicle-stimulating hormone levels, a seminal fructose test, post-ejaculate urinalysis and, sometimes, vasography. Transrectal ultrasonography, a technique currently familiar to most urologists, recently has been added to our diagnostic armamentarium. This office-based imaging procedure provides an accurate assessment of the prostate, ejaculatory ducts and seminal vesicles, which can be helpful in the evaluation of certain infertile patients. We describe 3 patients who presented with either azoospermia or decreased ejaculate volume in whom transrectal ultrasonography had a critical role in the fertility evaluation. The clinical indications for and interpretation of transrectal ultrasonography in the infertile population are described. Transrectal ultrasonography currently is the most accurate, inexpensive and readily available noninvasive imaging technique used to diagnose obstruction of the ejaculatory ducts in the infertile patient with either azoospermia or low ejaculate volume.

Entities:  

Mesh:

Year:  1990        PMID: 2231947     DOI: 10.1016/s0022-5347(17)39771-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Endoscopic management of ejaculatory duct obstruction.

Authors:  A Aggour; H Mostafa; W Maged
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  Ultrasound and infertility: diagnostic and therapeutic uses.

Authors:  M Zahalsky; H M Nagler
Journal:  Curr Urol Rep       Date:  2001-12       Impact factor: 2.862

Review 3.  Management of ejaculatory duct obstruction: etiology, diagnosis, and treatment.

Authors:  Harry Fisch; Sarah M Lambert; Erik T Goluboff
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.